Immunoglobulin E (IgE) specific to Blattella germanica allergens (sIgE (B. germanica))

Immunoglobulin E (IgE) antibodies specific to German cockroach (Blattella germanica) allergens are specialized proteins produced by the immune system in response to exposure to cockroach-derived proteins such as Bla g 1 and Bla g 2 (WHO/IUIS Allergen Nomenclature). These antibodies play a central role in the pathogenesis of allergic diseases, particularly in urban settings where cockroach infestation is a major risk factor for asthma morbidity (PMID: 9135072). In sensitized individuals, these specific IgE (sIgE) molecules bind to high-affinity FcεRI receptors on mast cells and basophils. When the patient is re-exposed to cockroach allergens, the allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (PMID: 21457342). This process leads to airway inflammation, mucus production, and bronchoconstriction, characterizing the clinical manifestations of allergic asthma. Therapeutic targeting of these antibodies is primarily achieved through the use of Omalizumab, a humanized monoclonal antibody that binds to the Fc region of free IgE (PMID: 12743352). By sequestering free IgE, Omalizumab prevents its interaction with receptors and subsequently downregulates receptor expression on effector cells. This intervention is particularly effective for managing severe, persistent allergic asthma in patients who demonstrate sensitivity to cockroach allergens.

Other names

Cockroach-specific IgEAnti-cockroach IgEBlattella germanica specific IgEsIgE to Bla g allergensGerman cockroach IgE

Binding to the Cε3 domain of free IgE to prevent its interaction with high-affinity FcεRI and low-affinity FcεRII (CD23) receptors, thereby inhibiting the allergic inflammatory cascade (PMID: 12743352).